Table 2.
Study | Sample-size calculation | Inclusion and exclusion criteria | Randomization | Allocation concealment | Reporting of animals excluded from analysis | Blinded assessment of outcome | Reporting potential conflicts of interest and study funding |
---|---|---|---|---|---|---|---|
Sun, J.Z. 201965 | Unclear | Unclear | Low | Unclear | Low | Unclear | Unclear |
Liu, X. 201866 | Unclear | Unclear | Low | Unclear | Unclear | Unclear | Unclear |
Wang, P. 201767 | Unclear | Unclear | Low | Unclear | Unclear | Low | Unclear |
Cong, L. 201668 | Unclear | Low | Low | Unclear | Unclear | Low | Unclear |
Sun, J.Z. 201569 | Unclear | Unclear | Low | Unclear | Low | Unclear | Unclear |
Liu, Y.L. 201570 | Unclear | Low | Low | Unclear | Unclear | Low | Unclear |
Li, Q. 201371 | Unclear | Low | Low | Unclear | Unclear | Unclear | Unclear |
Song, Y.X. 200972 | Unclear | Low | Low | Unclear | Unclear | Unclear | Unclear |
Sakanaka, M. 200773 | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear | Unclear |
Guo, D.Q. 200474 | Unclear | Low | Low | Unclear | Unclear | Low | Unclear |
SD, Sprague-Dawley; T, thoracic vertebrae, SCI, spinal cord injury; GS Rd, Ginsenoside Rd; i.p., intraperitoneal; BBBs, Basso-Beattie-Bresnahan locomotor rating scale; HE staining, hematoxylin-eosin staining; SOD, Superoxide Dismutase; MDA, malondialdehyde.